X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sterling Biotech with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs ACTAVIS (US) - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 STERLING BIOTECH   ACTAVIS
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
ACTAVIS
Dec-14
STERLING BIOTECH/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1117,421-   
Low Rs310,626-   
Sales per share (Unadj.) Rs26.83,137.0-  
Earnings per share (Unadj.) Rs-15.0-391.5-  
Cash flow per share (Unadj.) Rs-5.5287.8-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs54.96,804.1-  
Shares outstanding (eoy) m267.87265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.5 5.8%   
Avg P/E ratio x-0.5-35.8 1.3%  
P/CF ratio (eoy) x-1.348.7 -2.6%  
Price / Book Value ratio x0.12.1 6.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,8623,728,890 0.0%   
No. of employees `0001.421.6 6.3%   
Total wages/salary Rs m5470-   
Avg. sales/employee Rs Th5,303.338,617.6 13.7%   
Avg. wages/employee Rs Th403.80-   
Avg. net profit/employee Rs Th-2,959.0-4,819.1 61.4%   
INCOME DATA
Net Sales Rs m7,181834,139 0.9%  
Other income Rs m43-2,082 -2.0%   
Total revenues Rs m7,223832,057 0.9%   
Gross profit Rs m947107,157 0.9%  
Depreciation Rs m2,543180,622 1.4%   
Interest Rs m4,37726,310 16.6%   
Profit before tax Rs m-5,931-101,857 5.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,472 0.0%   
Tax Rs m-1,924-5,237 36.7%   
Profit after tax Rs m-4,007-104,092 3.8%  
Gross profit margin %13.212.8 102.6%  
Effective tax rate %32.45.1 631.1%   
Net profit margin %-55.8-12.5 447.1%  
BALANCE SHEET DATA
Current assets Rs m14,335439,485 3.3%   
Current liabilities Rs m49,809320,513 15.5%   
Net working cap to sales %-494.014.3 -3,463.7%  
Current ratio x0.31.4 21.0%  
Inventory Days Days40358 695.3%  
Debtors Days Days17166 257.4%  
Net fixed assets Rs m55,432101,857 54.4%   
Share capital Rs m2680-   
"Free" reserves Rs m13,9350-   
Net worth Rs m14,7011,809,218 0.8%   
Long term debt Rs m9,478948,066 1.0%   
Total assets Rs m73,9883,315,701 2.2%  
Interest coverage x-0.4-2.9 12.4%   
Debt to equity ratio x0.60.5 123.0%  
Sales to assets ratio x0.10.3 38.6%   
Return on assets %0.5-2.3 -21.4%  
Return on equity %-27.3-5.8 473.7%  
Return on capital %-6.4-3.0 213.4%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Net fx Rs m1,8350-   
CASH FLOW
From Operations Rs m1,719143,238 1.2%  
From Investments Rs m-3,148-342,967 0.9%  
From Financial Activity Rs m1,426192,698 0.7%  
Net Cashflow Rs m-3-7,031 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 63.86 Rs / USD

Compare STERLING BIOTECH With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare STERLING BIOTECH With: PFIZER  J.B.CHEMICALS  MERCK LTD  NATCO PHARMA  SUN PHARMA  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views On News

Tata Chem: Suspension of Haldia Operations Drag Bottomline Lower (Quarterly Results Update - Detailed)

Aug 17, 2017

Interruption at Haldia plant and fire at Lostock facility hits operations during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Jan 18, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS